A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein‐bound drugs and the impact of errors in plasma protein binding

Predicting the pharmacokinetics of highly protein‐bound drugs is difficult. Also, since historical plasma protein binding data were often collected using unbuffered plasma, the resulting inaccurate binding data could contribute to incorrect predictions. This study uses a generic physiologically based pharmacokinetic (PBPK) model to predict human plasma concentration–time profiles for 22 highly protein‐bound drugs. Tissue distribution was estimated from in vitro drug lipophilicity data, plasma protein binding and the blood: plasma ratio. Clearance was predicted with a well‐stirred liver model. Underestimated hepatic clearance for acidic and neutral compounds was corrected by an empirical scaling factor. Predicted values (pharmacokinetic parameters, plasma concentration–time profile) were compared with observed data to evaluate the model accuracy. Of the 22 drugs, less than a 2‐fold error was obtained for the terminal elimination half‐life (t1/2, 100% of drugs), peak plasma concentration (Cmax, 100%), area under the plasma concentration–time curve (AUC0‐t, 95.4%), clearance (CLh, 95.4%), mean residence time (MRT, 95.4%) and steady state volume (Vss, 90.9%). The impact of fup errors on CLh and Vss prediction was evaluated. Errors in fup resulted in proportional errors in clearance prediction for low‐clearance compounds, and in Vss prediction for high‐volume neutral drugs. For high‐volume basic drugs, errors in fup did not propagate to errors in Vss prediction. This is due to the cancellation of errors in the calculations for tissue partitioning of basic drugs. Overall, plasma profiles were well simulated with the present PBPK model. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  K. Korzekwa,et al.  On the Nature of Physiologically-Based Pharmacokinetic Models –A Priori or A Posteriori? Mechanistic or Empirical? , 2017, Pharmaceutical Research.

[2]  J. Houston,et al.  Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. , 2012, Journal of pharmaceutical sciences.

[3]  A. Galetin,et al.  Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin , 2012, Drug Metabolism and Disposition.

[4]  J. Halladay,et al.  Consistency of the novel equations for determination of hepatic clearance and drug time course in liver that account for the difference in drug ionization in extracellular and intracellular tissue water. , 2012, Journal of pharmaceutical sciences.

[5]  S. Haddad,et al.  In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. , 2012, Journal of pharmaceutical sciences.

[6]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[7]  S. Haddad,et al.  Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. , 2011, Journal of pharmaceutical sciences.

[8]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. , 2011, Journal of pharmaceutical sciences.

[9]  Fabian Müller,et al.  Influence of Non-Steroidal Anti-Inflammatory Drugs on Organic Anion Transporting Polypeptide (OATP) 1B1- and OATP1B3-Mediated Drug Transport , 2011, Drug Metabolism and Disposition.

[10]  Hannah M Jones,et al.  Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling , 2011, Clinical pharmacokinetics.

[11]  L. Berezhkovskiy,et al.  The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. , 2011, Journal of pharmaceutical sciences.

[12]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[13]  P. Prusis,et al.  Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  J. Houston,et al.  Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.

[15]  Patrick Poulin,et al.  Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.

[16]  Hannah M. Jones,et al.  Modelling and PBPK Simulation in Drug Discovery , 2009, The AAPS Journal.

[17]  Jos H Beijnen,et al.  Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone , 2009, Drug Metabolism and Disposition.

[18]  K. Korzekwa,et al.  Impact of pH on plasma protein binding in equilibrium dialysis. , 2008, Molecular pharmaceutics.

[19]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[20]  M Baker,et al.  Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[22]  H. Kusuhara,et al.  FUNCTIONAL INVOLVEMENT OF RAT ORGANIC ANION TRANSPORTER 2 (SLC22A7) IN THE HEPATIC UPTAKE OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN , 2005, Drug Metabolism and Disposition.

[23]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[24]  M. Iwaki,et al.  NONLINEAR PHARMACOKINETICS OF PROPAFENONE IN RATS AND HUMANS: APPLICATION OF A SUBSTRATE DEPLETION ASSAY USING HEPATOCYTES FOR ASSESSMENT OF NONLINEARITY , 2005, Drug Metabolism and Disposition.

[25]  Robert J Riley,et al.  EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.

[26]  Kiyomi Ito,et al.  Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes , 2004, Pharmaceutical Research.

[27]  J. Polli,et al.  Midazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate , 2003, Pharmaceutical Research.

[28]  Yau Yi Lau,et al.  Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Scott L Cockroft,et al.  The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Franco Lombardo,et al.  Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.

[31]  Y. Sugiyama,et al.  Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[32]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[33]  R. Foster,et al.  EXTRAHEPATIC FIRST‐PASS METABOLISM OF NIFEDIPINE IN THE RAT , 1997, Biopharmaceutics & drug disposition.

[34]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[35]  L. Aarons,et al.  Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[36]  S. Sattari,et al.  Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acyl-glucuronidation of R-fenoprofen , 1997, European Journal of Drug Metabolism and Pharmacokinetics.

[37]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[38]  P. Rosenzweig,et al.  EEG profile of intravenous zolpidem in healthy volunteers , 1994, Psychopharmacology.

[39]  T. Guentert,et al.  Bioavailability of intramuscularly administered tenoxicam , 1993, Biopharmaceutics & drug disposition.

[40]  W. Martin,et al.  Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. , 1990, Biopharmaceutics & drug disposition.

[41]  A. Renwick,et al.  Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. , 1988, British journal of clinical pharmacology.

[42]  J. M. Lanao,et al.  Bioavailability of rectally administered naproxen , 1987 .

[43]  G. Nyberg,et al.  Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. , 1987, Biopharmaceutics & drug disposition.

[44]  D. Debruyne,et al.  Clinical Pharmacokinetics of Ketoprofen After Single Intravenous Administration as a Bolus or Infusion , 1987, Clinical pharmacokinetics.

[45]  E. U. Kölle,et al.  Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. , 1986, British journal of clinical pharmacology.

[46]  R. Winkle,et al.  Propafenone disposition kinetics in cardiac arrhythmia , 1984, Clinical pharmacology and therapeutics.

[47]  M. Eichelbaum,et al.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. , 1984, British journal of clinical pharmacology.

[48]  D. Greenblatt,et al.  Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. , 1983, Journal of pharmaceutical sciences.

[49]  S. Bryson.  Clinical Pharmacokinetics: Concepts and applications. , 1983 .

[50]  J. Houston,et al.  Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. , 1983, British journal of clinical pharmacology.

[51]  P Heizmann,et al.  Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.

[52]  M. Kendall,et al.  A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium , 1980, European Journal of Clinical Pharmacology.

[53]  M. Rawlins,et al.  Prazosin, pharmacokinetics and concentration effect , 1979, European Journal of Clinical Pharmacology.

[54]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[55]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[56]  K. Alexander,et al.  Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. , 1973, Journal of pharmaceutical sciences.

[57]  M. Schoog,et al.  Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic , 1973, Diabetologia.

[58]  R. Wolen,et al.  Physiological disposition of fenoprofen in man. 3. Metabolism and protein binding of fenoprofen. , 1972, The Journal of pharmacology and experimental therapeutics.

[59]  B. Rodda,et al.  Physiological disposition of fenoprofen in man. II. Plasma and urine pharmacokinetics after oral and intravenous administration. , 1972, Journal of pharmaceutical sciences.

[60]  A. Leo,et al.  Partition coefficients and their uses , 1971 .

[61]  Fahima Nekka,et al.  Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. , 2010, Journal of pharmaceutical sciences.

[62]  Kiyomi Ito,et al.  Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.

[63]  C. Regårdh,et al.  Pharmacokinetics of felodipine in patients with liver disease , 2004, European Journal of Clinical Pharmacology.

[64]  S. Loft,et al.  Bioavailability and pharmacokinetics of oxazepam , 2004, European Journal of Clinical Pharmacology.

[65]  T. Andersson,et al.  Pharmacokinetics of various single intravenous and oral doses of omeprazole , 2004, European Journal of Clinical Pharmacology.

[66]  K. Midha,et al.  Pharmacokinetics of chlorpromazine and key metabolites , 2004, European Journal of Clinical Pharmacology.

[67]  U. Bondesson,et al.  Clinical pharmacokinetics of clozapine in chronic schizophrenic patients , 2004, European Journal of Clinical Pharmacology.

[68]  U. Bondesson,et al.  Pharmacokinetics of haloperidol in psychotic patients , 2004, Psychopharmacology.

[69]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[70]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[71]  T. Ishizaki,et al.  Pharmacokinetics of haloperidol: an update. , 1999, Clinical pharmacokinetics.

[72]  G. Mckay,et al.  Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers , 1996, European Journal of Clinical Pharmacology.

[73]  G R Wilkinson,et al.  Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.